GSK in talks to acquire Nuvalent for more than $9 billion in biggest deal in over a decade: FT (opens in new tab)

The deal comes at a time of biotech dealmaking frenzy, driven by looming patent cliffs, newly buoyant public markets and drugmakers' race to bolster pipelines.